Quantcast
Last updated on April 18, 2014 at 6:54 EDT

Latest CDP323 Stories

2011-11-04 06:00:00

NEW YORK, Nov. 4, 2011 /PRNewswire/ -- Citeline, an Informa business unit, and the world's leading research authority on pharmaceutical clinical trials recently reviewed results presented at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS), a major multiple sclerosis conference which was held October 19-22, 2011 in Amsterdam. Phase III study of oral BG-12 in relapsing-remitting multiple sclerosis...

2011-10-20 01:00:00

PARIS, October 20, 2011 /PRNewswire/ -- - New findings from the pivotal TEMSO Phase III study presented today at the joint ECTRIMS / ACTRIMS Congress - - U.S. FDA Accepts New Drug Application for Teriflunomide for relapsing forms of MS - Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today new data from the pivotal TEriflunomide Multiple Sclerosis Oral (TEMSO) Phase III trial showing that once-daily oral teriflunomide significantly...

2009-12-07 14:48:58

Biogen Idec (NASDAQ: BIIB) today announced that its oral compound BG-12 (dimethyl fumarate) achieved key milestones in clinical trials for multiple sclerosis (MS) and rheumatoid arthritis (RA). In recent months, the last patient was enrolled in the CONFIRM trial, the second of two Phase III trials designed to evaluate the efficacy and safety of BG-12 as a monotherapy in patients with relapsing-remitting multiple sclerosis (RRMS). Both the DEFINE and CONFIRM Phase III trials are now fully...

2009-02-05 01:51:00

MELBOURNE, Australia, Feb.5 /PRNewswire/ -- Cytopia Limited (ASX: CYT) has successfully concluded dose-escalation in its oral Phase I study for CYT997, the company's anticancer vascular-disrupting agent (VDA). The primary objectives of this safety and tolerability study have been achieved. These were to determine the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) for the agent when administered orally in capsule form every two weeks to patients with a diverse range of...

2008-10-28 12:00:39

CAMBRIDGE, Mass., Oct. 28 /PRNewswire/ -- Peptimmune, Inc., a privately held biotechnology company, announced today that President & CEO Thomas P. Mathers will provide an update on the Company's current phase Ib clinical trial for PI-2301 in multiple sclerosis patients at the three upcoming events: 1. BIO Investor Forum 2008. The presentation will take place on Wednesday, October 29th, at 3:15 p.m. in the Pacific Room at the Palace Hotel in San Francisco. 2. Oppenheimer...

2008-10-23 18:00:09

Biogen Idec (NASDAQ: BIIB) today announced the publication of Phase IIb data showing that a 240 mg three-times-daily dose of the company's novel oral compound, BG-12 (BG00012, dimethyl fumarate), reduced the number of new gadolinium enhancing (Gd+) lesions by 69 percent in patients with relapsing-remitting multiple sclerosis (MS) when compared to treatment with placebo (p BG-12 is the first compound that has been shown to activate the Nrf2 transcriptional pathway, which previous studies...

2008-10-09 18:00:37

Biogen Idec (NASDAQ: BIIB) announced today that its Phase II trial of baminercept (BG9924, LT(beta)R-Ig) in rheumatoid arthritis (RA) patients who have had an inadequate response to conventional therapy with a disease-modifying antirheumatic drug (DMARD) did not meet its primary endpoint. The primary endpoint was defined as the proportion of baminercept-treated patients who achieved an ACR50 response, a standard measure of disease improvement in RA, compared to placebo at 14 weeks. The study...

2008-09-16 15:00:11

CAMBRIDGE, Mass., Sept. 16 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced today that Dr. Joseph Kovalchin will make a poster presentation titled "Evidence of Specific T-cell Priming from the First-in-Man Single Ascending Dose Study of Peptide Copolymer PI-2301 for the Treatment of Multiple Sclerosis " on Thursday, September 18th from 3:30 - 5:00 p.m. in Exhibit Hall 220C, at the Palais Des Congres de Montreal, Canada at the World Congress on Treatment and...

2008-09-11 12:00:43

US-based biopharmaceutical company XenoPort has announced plans to initiate an exploratory Phase II clinical trial of XP19986 in patients with acute back spasms, which is a debilitating condition affecting approximately two-thirds of patients experiencing lower back pain. XenoPort intends to initiate this two-week, multi-center, double-blind, placebo controlled trial in the fourth quarter of 2008. The primary objective of the study will be to evaluate the safety and tolerability of XP19986...

2008-09-02 12:00:34

Research and Markets (http://www.researchandmarkets.com/research/f0d42d/cns_drug_discoveri) has announced the addition of the "CNS Drug Discoveries: Multiple Sclerosis Chapter" report to their offering. This chapter of CNS Drug Discoveries focuses on the multiple sclerosis market. With the launch of up to 12 new disease-modifying agents, three vaccines and one novel drug designed to treat the symptoms of multiple sclerosis (MS) and improve quality of life, the MS market is in an...